Belite Bio, Inc. (NASDAQ: BLTE) has started an underwritten public offering of American Depositary Shares, with all securities being sold by the company. The offering is aimed at raising funds for commercialization preparation, pipeline development, and general corporate purposes. The offering is being managed by Morgan Stanley & Co. LLC, Leerink Partners, BofA Securities, and Cantor. Interested parties can obtain more information about the offering from the SEC website or the underwriters. Belite Bio is a clinical-stage drug development company focusing on degenerative retinal diseases and has lead candidate Tinlarebant in trials for various conditions.

This press release contains forward-looking statements regarding the terms of the proposed public offering and completion details. Actual results may differ due to factors beyond Belite Bio’s control. The company’s ability to demonstrate drug safety and efficacy, clinical trial results, and regulatory approval are key factors influencing outcomes. Investors should consider the risks involved as outlined in Belite Bio’s filings with the U.S. Securities and Exchange Commission. Media and investor relations contacts are available for further information and inquiries.

Read more at GlobeNewswire: Belite Bio Announces Proposed Underwritten Public Offering